Company UpdateEarnings Call Transcript
Anupam Rasayan Q1 FY27: 36% revenue growth, ETFA flow chemistry milestone, Jayhawk and Bliss progress amid robust pipeline
Financial Performance
- Q1 FY27 consolidated total income INR668 crores, up 36% YoY.
- Revenue from operations INR655 crores in Q1 FY27.
- Consolidated EBITDA INR174.9 crores; margin 26%.
- PAT INR51.2 crores; PAT margin ~8%.
- Cash profit INR64 crores; vs INR56 crores in Q1 FY26.
- Depreciation higher due to asset base expansion and Jayhawk.
- Major capex cycle completed; near-term capex for existing platform not significant.
- Standalone gross margin 58% in the quarter.
Operating Highlights
- ETFA commercialization via flow chemistry marks milestone; unique scale advantages.
- 65+ pharma/polymer molecules in R&D; 10+ molecules commercialized in 2 years.
- LOI with BASQUEVOLT for potential USD 300 million over 10 years; commercialization FY27.
- Jayhawk acquisition strengthens US manufacturing, advanced chemistries, and global reach.
- Bliss GVS Pharma acquisition progressing; SEBI approval done; open offer concluded Aug 10; close expected in H1 Sep.
- Jayhawk contributed ~20-22% of quarterly revenue; EBITDA margin ~19-20%.
Portfolio Share and Mix
- Polymer share: standalone 20-25%; consolidated 30-35%.
- Agri demand recovering; performance materials and pharma share rising.
Capex and Cash Flow
- Major capex cycle completed; limited near-term capex for existing platform.
- Standalone capex guidance for FY27: INR 70-80 crores.
- Cash generation healthy; working capital largely stable; improvement expected in FY27.
Outlook and Guidance
- Organic revenue growth guidance for FY27: 25% +/- 2%.
- Jayhawk addition expected to add ~10-15% growth; revenue mix shifts persist.
- Standalone EBITDA margin guide: 24-26%; consolidated: 22-24%.
- ETFA market potential around USD 0.5 billion; ramp-up in 2–3 years.
- LOI/contracts referenced: INR 18,000 crores of potential business over tenures.
Q&A Highlights
- Bliss acquisition: expected consummation by H1 Sep; integration to begin post-close.
- Bliss independence approach maintained; synergy with Jayhawk and Anupam’s teams planned.
- Jayhawk quarterly revenue ~INR 145 crores; EBITDA ~INR 30 crores (19-20%).
- Standalone gross margin ~58% this quarter; EBITDA-focused view remains key.
- Capex outlook: INR 70-80 crores for next year; little else required.